News

Novo Nordisk to sell weight-loss drug for $499 to eligible customers

Cash-paying type 2 diabetes patients in the United States can now access Novo Nordisk's Ozempic for $499 per month through ...

Why Novo Nordisk Stock Popped Monday

Shares of Novo Nordisk ( NVO 4.81%), the Danish pharmaceuticals company famed for Ozempic and Wegovy weight loss drugs, ...
PharmExec1m

Novo Nordisk Announces Lower Cost of Ozempic to $499-Per-Month for Self-Paying Patients

Novo Nordisk reduces Ozempic's price to $499/month for self-paying patients, enhancing access to essential diabetes treatment ...

Novo Nordisk's Loss Is Eli Lilly's Gain, And Vice Versa

Novo Nordisk A/S gains momentum with FDA approval for Wegovy and strategic pricing. Click for why Novo outshines Eli Lilly ...

Stocks to Watch Monday: Novo Nordisk, TeraWulf, UnitedHealth, Soho House

The Food and Drug Administration approved Novo Nordisk's popular weight-loss drug Wegovy to treat a [form of liver disease]( ...

Wall Street sees new obesity pills as priced near Wegovy and Zepbound

U.S. prices for obesity-treatment pills that Eli Lilly and Novo Nordisk aim to launch next year likely will be on par with ...
Zacks.com on MSN3d

Will New CEO's Leadership Propel Novo Nordisk's Next Growth Wave?

Maziar Mike Doustdar takes office as NVO's new CEO, bringing a proven global growth record to tackle rising obesity market ...
Medical Dialogues3d

Novo Nordisk Launches Wegovy in South Africa, Ramping Up Obesity Drug Battle with Eli Lilly

Johannesberg: Danish drugmaker Novo Nordisk introduced its weight-loss drug Wegovy in South Africa on Thursday, marking its debut in Africa and stepping up competition with Eli Lilly's ...